MBL and MASP-2 concentrations in serum and MBL2 promoter polymorphisms are associated to schizophrenia.

Abstract

Objective:Causative relations between infections and psychosis, especially schizophrenia, have been speculated for more than a century, suggesting a hypothesis of association between schizophrenia and hereditary immune defects. Mannan-binding lectin (MBL) is a pattern-recognition molecule of the innate immune defence. MBL deficiency is the most common hereditary defect in the immune system and may predispose to infection and autoimmunity. Mannan-binding lectin serine protease-2 (MASP-2) is an MBL-associated serine protease mediating complement activation upon binding of MBL/MASP to microorganisms. The objective was to investigate if schizophrenia is associated with serum concentrations of MBL and MASP-2 or with genetic variants of the genesMBL2andMASP2encoding these proteins.Methods:The sample consisted of 100 patients with schizophrenia and 350 controls. Concentrations of MBL and MASP-2 in serum were measured and seven single nucleotide polymorphisms known to influence these concentrations were genotyped.Results:Significant association of disease with genetic markers was found inMBL2but not inMASP2. Significant difference in MBL serum concentration was found between patients and controls when adjusting forMBL2haplotypes. For concentrations of MASP-2, a significant interaction effect between aMASP2variant and disease was found. Interestingly, MASP-2 levels also depended significantly on variants inMBL2exon 1.Conclusion:This study supports previous studies showing increased complement activity in patients with schizophrenia, indicates aetiological heterogeneity among patients and underlines that multilocus genotypes have to be considered when investigating effects on MBL level. It appears that inclusion of additional components from the system of complement activation is warranted.